Rapport Therapeutics, Inc.

Rapport Therapeutics reported a Q2 2026 net loss of $56.6 million, widening from $26.7 million in Q2 2025. For the six months, net loss was $76.5 million, driven by a 126% increase in research and development expenses to $51.4 million in Q2 2026. The company recognized $20 million in collaboration revenue for the six-month period and ended the quarter with $436.1 million in cash, cash equivalents, and short-term investments, expecting to fund operations for at least 12 months.

Rapport Therapeutics reported a net loss of $56.6 million for the second quarter of 2026, an increase from $26.7 million in the prior year, primarily due to higher R&D expenses of $51.4 million. Despite the increased loss, the company announced significant pipeline progress, including the initiation of its RAP-219 Phase 3 program for focal onset seizures and anticipated topline results in October 2026 for the RAP-219 Phase 2 trial in bipolar mania. Rapport ended the quarter with a strong cash position of $436.1 million, providing a cash runway into the second half of 2029.

Rapport Therapeutics, Inc. announced that its management plans to participate in two upcoming investor conferences. These include a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, and another at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026. Interested parties can access live and archived webcasts of these events through the company's investor relations website.

Rapport Therapeutics reported a reduced net loss of $19.9 million for the first quarter of 2026, a significant improvement from the $24.1 million loss in the same period last year. This was primarily driven by the recognition of $20 million in collaboration revenue, which was absent in the prior year. The company ended the quarter with $476.8 million in cash, cash equivalents, and short-term investments, which is expected to fund operations for at least the next 12 months, though additional financing will be required for its growth strategy.

Rapport Therapeutics reported Q1 2026 financial results and provided a business update, highlighting positive Phase 2a follow-up data for RAP-219 in focal onset seizures, showing a 90% median reduction in clinical seizures. The company also accelerated the expected topline results for its RAP-219 Phase 2 trial in bipolar mania to Q4 2026. Financially, Rapport reported a net loss of $19.9 million, improved from the prior year, and generated $20.0 million in collaboration revenue from a new strategic agreement with Tenacia Biotechnology for RAP-219 in Greater China. The company ended the quarter with $476.8 million in cash, extending its cash runway into the second half of 2029.

Rapport Therapeutics announced positive results from the 8-week follow-up period of its Phase 2a trial for RAP-219 in focal onset seizures (FOS). The trial demonstrated sustained seizure reduction and continued biomarker and clinical responses. This sustained effect is attributed to RAP-219's long half-life, maintaining therapeutic levels post-treatment.

Rapport Therapeutics announced positive follow-up results from its Phase 2a trial of RAP-219 for focal onset seizures. The drug demonstrated clinically meaningful efficacy, with a 90% median reduction in clinical seizures during weeks 9-12 and a 59% reduction during weeks 13-16, due to its sustained therapeutic levels. The estimated half-life of RAP-219 has been revised to approximately 22 days, up from 14 days, and it was well tolerated.